Phase I trial evaluating the bioavailability, bioactivity and safety of two intranasal formulations of somatropin [CP 024] versus subcutaneously injected marketed human growth hormone in healthy volunteers

Trial Profile

Phase I trial evaluating the bioavailability, bioactivity and safety of two intranasal formulations of somatropin [CP 024] versus subcutaneously injected marketed human growth hormone in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2013

At a glance

  • Drugs Somatropin (Primary) ; Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 21 Nov 2013 New trial record
    • 06 Sep 2011 Interim data reported in a Critical Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top